Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

FDA Approves Ziftomenib for NPM1+ R/R Acute Myeloid Leukemia

November 13th 2025

Ziftomenib has received FDA approval for the treatment of adult patients with relapsed or refractory acute myeloid leukemia harboring an NPM1 mutation.

Dr Visco on Ongoing Research to Optimize Upfront MCL Therapy

November 13th 2025

Carlo Visco, MD, discussed notable ongoing MCL research and the emerging challenge of optimally sequencing therapies for the management of this disease.

How a Career Dedicated to Patient Connections and Research Advances Has Improved Lung Cancer Care: With D. Ross Camidge, MD, PhD; and Mark Socinski, MD

November 12th 2025

Drs Camidge and Socinski discussed the highlights of Dr Socinski's career trajectory and the personal influences that helped him arrive where he is today.

Dr Orloff on OS Outcomes With Darovasertib Plus Crizotinib in Metastatic Uveal Melanoma

November 12th 2025

Marlana Orloff, MD, discusses efficacy findings with darovasertib plus crizotinib in metastatic uveal melanoma that were seen in the OptimUM-01 trial.

Dr Liu on the Efficacy of Zidesamtinib in ROS1 Fusion+ NSCLC

November 12th 2025

Stephen Liu, MD, discussed efficacy data with zidesamtinib in ROS1 fusion–positive non-small cell lung cancer that were reported in the ARROS-1 trial.

Dr Camidge on the Efficacy and Safety of Neladalkib in ALK+ Solid Tumors

November 12th 2025

D. Ross Camidge, MD, PhD, discusses safety and efficacy data seen with neladalkib in TKI-naive and -pretreated patients with ALK-positive solid tumors.

Dr Bellmunt on the Design of the IMvigor011 Trial of ctDNA-Guided Adjuvant Atezolizumab in MIBC

November 12th 2025

Joaquim Bellmunt, MD, PhD, discusses the phase 3 IMvigor011 trial of ctDNA-guided adjuvant atezolizumab in MIBC.

Dr George on the Role of Radioligand Therapy in Prostate Cancer Management

November 12th 2025

Daniel J. George, MD, discusses the potential of radioligand therapies for patients with prostate cancer and the evolution of this treatment paradigm.

Emerging ADC Data and Combination Strategies Are Set to Redefine First-Line TNBC Management

November 12th 2025

Joyce O'Shaughnessy, MD, discusses ways that data with sacituzumab govitecan and Dato-DXd may shift treatment standards for patients with mTNBC.

Anito-Cel Emerges as Potential Novel Option in R/R Multiple Myeloma

November 12th 2025

Anito-cel produced high ORR and sCR/CR rates in patients with relapsed/refractory multiple myeloma.

Oncology Experts and AI Advocates Explain the Evolving Role of AI in Insurance Appeals

November 12th 2025

Using AI to automate oncology insurance prior authorization submissions could help lighten the load for health care professionals and speed access to care.

Unique Challenges Characterize Treatment Outcomes for Women With Bladder Cancer: With Martha K. Terris, MD, FACS

November 11th 2025

Dr Terris discusses disparities in treatment and outcomes for women with bladder cancer and summarized reasons for this poor prognosis.

Oncology Experts Debate the Potential for AI to Improve Timely Access to Care

November 11th 2025

Incorporating AI into daily workflows may allow oncology professionals to save time on insurance denial claims and re-allocate time back into patient care.

At 3 Years, Eque-Cel Displays Deep and Durable Responses in Relapsed Multiple Myeloma

November 11th 2025

Long-term data reveal deep remissions with eque-cel, suggesting durable disease control with BCMA-directed CAR T-cell therapy in relapsed multiple myeloma.

Urothelial ESMO 2025 Updates

November 11th 2025

OncLive partnered with Two Onc Docs to review updates from the 2025 ESMO Congress on bladder cancer management that may change guidelines.

Camizestrant Plus CDK4/6 Inhibition Causes Minimal Effect on Visual QOL in HR+, ESR1-Mutated Breast Cancer

November 7th 2025

Use of camizestrant plus a CDK4/6 inhibitor at the emergence of an ESR1 mutation did not significantly worsen visual symptoms in HR-positive breast cancer.

Giredestrant/Everolimus Opens Doors for Improved SERD Regimens for ER+, Endocrine-Resistant Breast Cancer

November 7th 2025

Erica L. Mayer, MD, MPH, discusses data with giredestrant and how the evERA trial shows the potential for SERD-based regimens in ER-positive breast cancer.

Research Innovations Spark Promise for Broadening the HR+ Breast Cancer Armamentarium Post-CDK4/6 Inhibition: With Kevin Kalinsky, MD, MS, FASCO

November 7th 2025

Dr Kalinsky discusses the treatment paradigm for HR-positive breast cancer post-CDK4/6 inhibition and the need for therapeutic advances in this setting.

BVd Approval Reframes Considerations Around Sequencing BCMA-Targeted Therapies in R/R Myeloma

November 7th 2025

Surbhi Sidana, MD, and Joshua Richter, MD, discuss the FDA approval of BVd for relapsed/refractory myeloma after at least 2 prior lines of therapy.

ARROS-1 Data Show Zidesamtinib's Favorable Safety Profile, Spark Discussion to Clarify Its Role in ROS1+ NSCLC: With Stephen Liu, MD

November 6th 2025

Dr Liu discusses the potential role for zidesamtinib for the treatment of patients with advanced non–small cell lung cancer harboring ROS1 rearrangements.